Navigation Links
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Date:5/28/2009

he New England Journal of Medicine.

In this second study, mortality at 12 months in patients receiving Prograf/MMF (2.7%) was similar compared to patients receiving cyclosporine/MMF (3.3% and 1.8%) or sirolimus/MMF (3.0%). Patients in the Prograf group exhibited higher estimated creatinine clearance rates (eCLcr) using the Cockcroft-Gault formula and experienced fewer efficacy failures, defined as biopsy proven acute rejection (BPAR), graft loss, death and/or lost to follow-up in comparison to each of the other three groups: Prograf/MMF (20.4%), CyA/MMF (36.2% and 31.6%) and Siro/MMF (46.4%).

Median creatinine clearance rate, a measure of kidney function (eCLcr) at 12 months was higher in the Prograf group (66.2ml/min) than in the other three groups (range, 56.9 to 60.9ml/min). The BPAR was also lowest (15.0%) in the Prograf arm when compared to the standard-dose CyA (29.0%), low-dose CyA (26.6%) or sirolimus (38.1%) groups. Graft loss excluding death was also lowest in the low-dose Prograf group (3.0%), followed by the low-dose CyA group (5.0%), the standard-dose CyA (7.2%) and the sirolimus group (7.5%).

"After more than 20 years of commitment to the fields of immunology and transplantation, Astellas remains dedicated to the advancement of the science of immunosuppression to enhance the care of transplant patients," said M. Roy First, M.D., Vice President, Therapeutic Area Head, Transplantation for Astellas. "The approval of Prograf + MMF for use in kidney transplant patients provides further evidence of Astellas' ongoing commitment to developing the field of immunology and transplantation."

About Prograf(R) (tacrolimus)

Prograf(R) (tacrolimus capsules and injection) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be
'/>"/>

SOURCE Astellas
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
2. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
3. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
4. CV Therapeutics Statement on Unsolicited Proposal From Astellas
5. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
6. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
7. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
8. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
9. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
10. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... is being held on October 29-30 in San Francisco, ... industry, academic and government researchers and clinicians focused on ... space. , In the twelve years since the ... therapies have been introduced with pharmacogenetic information in the ...
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Cellgen Diagnostics today ... fund a corporate lab for its genetic-based medical ... is a critical component in the move from ... implementation of personalized medicine – a more predictive, ... Indiegogo contributions will support Cellgen’s intent to develop ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... the most promising biotech start-up company at the recent ... a proprietary process to convert wastewater from food and ... was given top honors out of 22 total entries ... from the sponsoring Colorado law firm of Dorsey & ...
... 8 Prosolia, Inc. introduces a new,advanced Omni Spray Ion ... Omni Spray 2-D Ion Source has an automated,surface platform which ... up to 76 mm by 114 mm, which is the ... The Omni Spray 2-D Ion Source ...
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
Cached Biology Technology:Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 2Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 3Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 4Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 5Prosolia to Introduce Omni Spray(R) Ion Source in 2-D Format 2Adecco Receives Honor From Alcon Laboratories 2
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Xanex or Xanax? Or maybe Zantac? If you're a health ... , An estimated 1.3 million people in the United States ... U.S. Federal Drug Administration (FDA) has been working to reduce ... in which a patient needed an injection of Narcan but ...
... Genes & Development, Dr. Mary Ellen Perry and colleagues ... for cancer therapies. , The p53 tumor suppressor plays ... strategies aim to activate p53 in order to curb ... and therefore an attractive target to modulate p53 activity ...
... death by suicide generally decreases in the weeks after ... study led by Group Health Cooperative researchers and published ... Psychiatry. The study also found that the risk of ... less than the risk posed by older medications. ...
Cached Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
Biology Products: